NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug

Novo Nordisk (NYSE:NVO) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity.The expansion will be built in North Carolina and is part of a $11 billion global production push.Novo Nordisk, which is based in Denmark but trades in New York with the NVO stock ticker, rose 2% overnight to $145 per share.The Tesla of PharmaNovo Nordisk pioneered Glucagon-Like Peptide 1 (GLP-1) agonists, generally taken b ...